Immunic Stock Beneish M Score

IMUX Stock  USD 1.20  0.06  5.26%   
This module uses fundamental data of Immunic to approximate the value of its Beneish M Score. Immunic M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Immunic Piotroski F Score and Immunic Altman Z Score analysis.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
  
Short Term Debt is likely to rise to about 797.9 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 955.9 K in 2024. At this time, Immunic's Book Value Per Share is fairly stable compared to the past year. Capex To Depreciation is likely to rise to 3.16 in 2024, whereas PTB Ratio is likely to drop 1.46 in 2024.
At this time, it appears that Immunic is an unlikely manipulator. The earnings manipulation may begin if Immunic's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Immunic executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Immunic's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.96
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

-0.0217

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

0.7

Focus

Immunic Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Immunic's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables1.3 M703 K
Way Up
Slightly volatile
Total Assets81.3 M54.3 M
Way Up
Slightly volatile
Total Current Assets70.8 M52.5 M
Significantly Up
Slightly volatile
Non Current Assets Total1.7 M1.8 M
Notably Down
Slightly volatile
Property Plant Equipment251.4 K264.6 K
Notably Down
Slightly volatile
Depreciation And Amortization105.5 K111 K
Notably Down
Slightly volatile
Selling General Administrative14 M16 M
Fairly Down
Slightly volatile
Total Current Liabilities26 M24.7 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total607 K639 K
Notably Down
Slightly volatile

Immunic Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Immunic's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Immunic in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Immunic's degree of accounting gimmicks and manipulations.

About Immunic Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

105,450

At this time, Immunic's Depreciation And Amortization is fairly stable compared to the past year.

Immunic Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Immunic. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables408K1.6M2.2M2.7M703K1.3M
Total Assets66.0M167.9M139.1M127.8M54.3M81.3M
Total Current Assets32.2M133.7M105.0M125.9M52.5M70.8M
Non Current Assets Total33.7M34.1M34.1M1.9M1.8M1.7M
Property Plant Equipment80K203K1.1M294K264.6K251.4K
Depreciation And Amortization50K39K85K77K111K105.5K
Selling General Administrative14.5M10.3M13.3M15.3M16.0M14.0M
Total Current Liabilities7.1M8.4M11.4M13.1M24.7M26.0M
Non Current Liabilities Total520K679K584K992K639K607.1K
Net Debt(28.8M)(126.8M)(86.3M)(105.2M)(45.3M)(47.6M)
Operating Income(37.0M)(49.0M)(91.7M)(119.5M)(99.2M)(94.3M)
Total Cash From Operating Activities(28.5M)(46.1M)(83.2M)(65.1M)(70.8M)(67.3M)
Investments10.5M(146K)(67K)(9.7M)9.5M9.9M

About Immunic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.